



DOCKET NO: B0192.70019US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Christine Van Broeckhoven et al.
Serial No.: 09/581,500
Confirmation No.: 9967
Filed: November 14, 2000
For: MOOD DISORDER GENE

Examiner: Diana B. Johannsen
Art Unit: 1634

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 18th day of October, 2004.


Melissa L. Barlow Lyons

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

1. The above-identified U.S. application claims priority to application Serial No. PCT/EP98/08543 and GB 9726804.9. If the Examiner has not had the benefit of review of the file history of PCT/EP98/08543 and GB 9726804.9, then he/she is asked to contact the undersigned, who will provide a copy of same.
2. The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application PCT/EP98/08543 filed on December 17, 1998 and published as WO 99/32643 A3.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.


By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,
Christine Van Broeckhoven et al., *Applicants*

By: 
John R. Van Amsterdam, Ph.D., Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 646-8000

Docket No. B0192.70019US00
Date: October 18, 2004
X10/18/04X



FORM PTO-1449A and B (Modified)				APPLICATION NO.: 09/581,500		ATTY. DOCKET NO.: B0192.70019US00			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: November 14, 2000		CONFIRMATION NO.: 9967			
				APPLICANT: Christine Van Broeckhoven, et al.					
				GROUP ART UNIT: 1634		EXAMINER: Diana B. Johannsen			
Sheet	1	of	3						

U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS


Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
	B1	WO	97/11175		Medical Research Council, et al.	03-27-1997	
	B2	WO	97/17445		Centre Nat Rech Scient. et al.	05-15-1997	
	B3	WO	97/37043		Univ of California, et al.	10-09-1997	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	BERRETTINI et al. Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. <i>Proc Natl Acad Sci U S A</i> 91(13):5918-21, 1994.		
	C2	BRESCHER, T.S., et al., A novel heritable expanding CTG repeat in an intron of the SEF2-1 gene on chromosome 18q21.1 Human Molecular Genetics, 6(11):1855-1863, 1997.		
	C3	COON et al, Analysis of chromosome 18 DNA markers in multiplex pedigrees with manic depression.. <i>Biol Psychiatry</i> . 39(8):689-96, 1996.		
	C4	DE BRUYN et al, Linkage analysis of families with bipolar illness and chromosome 18 markers. <i>Biol Psychiatry</i> . 39(8):679-688, 1996.		
	C5	EWALD, H., et al., Susceptibility loci for bipolar affective disorder on chromosome 18: a review and a study of Danish families. <i>Psychiatric Genetics</i> . 7:1-12, 1997.		
	C6	FREIMER et al, Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23. <i>Nat Genet</i> . 12(4):436-441, 1996.		
	C7	GENBANK Accession Number G03587 - human STS WI-1783, sequence tagged site - 19-OCT- 1995		
	C8	GENBANK Accession Number G03589 - human STS WI-528, sequence tagged site, 19-OCT-1995		
	C9	GENBANK Accession Number G03602 - human STS WI-2620, sequence tagged site, 19-OCT-1995		
	C10	GENBANK Accession Number G03617 human STS WI-4211, sequence tagged site, 19-OCT-1995		
	C11	GENBANK Accession Number G04207 - human STS WI-3170, sequence tagged site, 19-OCT-1995		



Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C12	GENBANK Accession Number G05278 human STS WI-5654, sequence tagged site, 19-OCT-1995	
	C13	GENBANK Accession Number G05488 - human STS WI-9959, sequence tagged site, 19-OCT-1995	
	C14	GENBANK Accession Number G06102 - human STS WI-9340, sequence tagged site, 19-OCT-1995	
	C15	GENBANK Accession Number G06377 human STS WI-7061, sequence tagged site, 19-OCT-1995	
	C16	GENBANK Accession Number G06527 human STS WI-7336, sequence tagged site, 19-OCT-1995	
	C17	GENBANK Accession Number G07990 human STS CHLC.GATA2E06.P6006 clone GATA2E06, sequence tagged site, 05-FEB-1997	
	C18	GENBANK Accession Number G08001 - human STS CHLC.GATA52H04.P16177 clone GATA52H04, sequence tagged site, 05-FEB-1997	
	C19	GENBANK Accession Number G08003, human STS CHLC.GATA69F01.P18099 clone GATA69F01, sequence tagged site, 05-FEB-1997	
	C20	GENBANK Accession Number G08015 human STS CHLC.GATA92C08.P28080 clone GATA92C08, sequence tagged site, 05-FEB-1997	
	C21	GENBANK Accession Number G09104 human STS CHLC.GATA3E08.P6051 clone GATA3E08, sequence tagged site 14-AUG-1995	
	C22	GENBANK Accession Number G09150 - human STS CHLC.GATA3E12.P6553 clone GATA3E12, sequence tagged site, 14-AUG-1995	
	C23	GENBANK Accession Number G09484 human STS CHLC.GCT3G01.P10825 clone GCT3G01, sequence tagged site, 14-AUG-1995	
	C24	GENBANK Accession Number G09963 - human STS CHLC.GATA61E10.P17745 clone GATA61E10, sequence tagged site, 15-AUG-1995	
	C25	GENBANK Accession Number G10262 - human STS CHLC.GATA117C05.P34272 clone GATA117C05, sequence tagged site, 15-AUG-1995	
	C26	GENBANK Accession Number L40377 - Homo sapiens cytoplasmic antiproteinase 2 (CAP2) mRNA, complete cds, 18-JAN-1996	
	C27	GENBANK Accession Number T49159 - yb09e07.s1 Stratagene placenta (#937225) Homo sapiens cDNA clone IMAGE:70692 3' similar to similar to gb:J02685 PLASMINOGEN ACTIVATOR INHIBITOR-2, PLACENTAL (HUMAN), MRNA sequence, Feb 6 1995	
	C28	GENBANK Accession Number X63657 - H.sapiens fvt1 mRNA, 30-JUN-1993	
	C29	GENBANK Accession Number Z16621 H. sapiens (D18S55) DNA segment containing (CA) repeat; clone AFM122xc1; single read, 28-NOV-1994	
	C30	GENBANK Accession Number Z16781 - H. sapiens (D18S60) DNA segment containing (CA) repeat; clone AFM178xe3; single read, 28-NOV-1994	
	C31	GENBANK Accession Number Z17122 - H. sapiens (D18S68) DNA segment containing (CA) repeat; clone AFM248yb9; single read, 28-NOV-1994	
	C32	GENBANK Accession Number Z23354 - H. sapiens (D18S466) DNA segment containing (CA) repeat; clone AFM094ye5; single read, 27-NOV-1994	



Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C33	GENBANK Accession Number Z23850 - H. sapiens (D18S465) DNA segment containing (CA) repeat; clone AFM260yh1; single read, 28-NOV-1994		
	C34	GENBANK Accession Number Z24399 H. sapiens (D18S483) DNA segment containing (CA) repeat; clone AFM324wc9; single read, 28-NOV-1994		
	C35	GOOSSENS et al., No evidence for the involvement of CAG/CTG repeats from within 18q21.33-q23 in bipolar disorder. E. J. of Hum. Genet. 8: 385-388, 2000.		
	C36	MCMAHON et al., Linkage of Bipolar Affective Disorder to Chromosome 18 Markers in a New Pedigree Series, Am. J. Hum. Genet. 61: 1397-1404, 1997.		
	C37	O'DONOVAN, M.C., et al., Expanded CAG repeats in schizophrenia and bipolar disorder. Nature Genetics. 10:380-381, 1995.		
	C38	SPENCE et al. Bipolar disorder: evidence for a major locus. <i>Am J Med Genet.</i> 60(5):370-6, 1995.		
	C39	STINE et al. Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. <i>Am J Hum Genet.</i> 57(6):1384-94, 1995.		
	C40	TURECKI, G., et al., Evidence for a role of phospholipase C-Gamma.1 in the pathogenesis of bipolar disorder. <i>Molecular Psychiatry.</i> 3(6):534-538, 1998.		
	C41	VERHEYEN, G.R., et al., Genetic refinement and physical mapping of a chromosome 18q candidate region for bipolar disorder. <i>Eur. J. Human Genetics.</i> 7(4):427-434, 1999.		

EXAMINER	DATE CONSIDERED
----------	-----------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]